title: The Administration of Celecoxib as an Analgesic after Liver Resection Is Safe.
abstract: BACKGROUND
  There are a few studies that have evaluated postoperative analgesia. The aim of this study was to evaluate the safety of administering celecoxib to manage postoperative pain after liver surgery.
  
  
  METHODS
  The cases of patients who underwent liver resection at Nara Medical University from April 2008 to December 2015 were retrospectively analyzed. From January 2013 to December 2015, celecoxib was routinely administered (600 mg/day on postoperative day (POD) 2 and 400 mg/day from POD 3-7), whereas celecoxib was not administered from April 2008 to December 2012. The patients' baseline characteristics, the operative procedures, and postoperative complications were analyzed.
  
  
  RESULTS
  In total, 207 patients were administered celecoxib (celecoxib group), whereas 246 were not (non-celecoxib group). The preoperative serum total bilirubin and creatinine levels and indocyanine green retention rate at 15 min values of the 2 groups were similar. Similar incidences of overall and major complications (Clavien-Dindo classification ≥grade IIIa) were seen in both groups (33.8 vs. 36.2%, p = 0.601 and 12.1 vs. 12.6%, p = 0.866, respectively). No significant differences in the incidences of gastrointestinal bleeding, acute renal failure, or portal vein thrombosis were observed between the groups.
  
  
  CONCLUSIONS
  The use of celecoxib for postoperative analgesia in the early period after liver resection is safe.
authors.affiliation: Department of Surgery, Nara Medical University, Nara, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Hokuto
authors.forename: Takeo
authors.initials: T
authors.lastname: Nomi
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kawaguchi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yasuda
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Obara
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yamato
authors.forename: Takatsugu
authors.initials: T
authors.lastname: Yamada
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Kanehiro
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakajima
mesh_terms: D058186:Acute Kidney Injury / Q000453:epidemiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D000068579:Celecoxib / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000453:epidemiology*; D006498:Hepatectomy / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy* / Q000209:etiology; D011169:Portal Vein; D019106:Postoperative Hemorrhage / Q000453:epidemiology*; D012189:Retrospective Studies; D020246:Venous Thrombosis / Q000453:epidemiology*; D055815:Young Adult
chemical_list: D000700:Analgesics; D000068579:Celecoxib